Seeking Alpha

Proactive Investor's  Instablog

Proactive Investor
Send Message
Proactiveinvestors is a leading multimedia news organization, investor portal and events management business with offices in New York, Sydney, Toronto and London. Proactiveinvestors operates five financial websites in four languages providing breaking news, comment and analysis on hundreds of... More
My company:
Proactiveinvestors
My blog:
Proactiveinvestors
  • Allied Healthcare Group Unlocks Further Potential Of Regenerative Tissue Technology  0 comments
    Jan 9, 2013 7:56 PM

    Allied Healthcare Group (ASX: AHZ) is achieving further success in the development of its ADAPT®-treated tissue as a bioprosthetic substitute for abdominal hernia repairs as well as pelvic floor reconstructions.

    A comparative study carried out on an experimental model showed the ADAPT® tissue was superior or equal to the comparative synthetic implant.

    No macroscopic evidence of calcification or visible immunological responses was found in the explanted ADAPT®-treated tissue in both the hernia and pelvic floor reconstructions at the end of the study period.

    Significantly, these positive results expand the potential for ADAPT®-treated tissue to be used in other applications, opening up potential new revenue streams.

    Lee Rodne, managing director, commented: "These results are significant in building further revenue in areas outside of CardioCel® for cardiovascular applications.

    "With combined markets of over $750 million we are excited about the future prospects of building significant revenue for our group and bringing to market innovative regenerative tissue products developed from our Regenerative Medicine Division."

    Assessment of the physical properties of the explanted ADAPT®-treated tissues after six months demonstrated a better outcome than the control.

    The ADAPT®-treated tissue remained stable and intact without any significant deformation of the original shape (configuration) and size (dimensions) compared to synthetic meshes which tended to contract and shrink.

    For hernia repair, the study demonstrated the outstanding performance of ADAPT®-treated tissue as a substitute for abdominal hernia repairs compared to alternative synthetic controls which tend to fail due to tissue erosion, implant exposure and infections after implantation.

    For pelvic floor repairs, the macroscopic results with the ADAPT®-treated tissue in the pelvic floor reconstructions demonstrated comparable results in the vaginal area with the synthetic controls.

    These results compared favourably in terms of maintaining significantly low rates of implant exposure, erosion of surrounding tissue and infection when compared to synthetic materials currently in the market place.

    The study was undertaken in collaboration with world known gynecologist, Professor Jan Deprest, from The University of Leuven in Belgium.

    Firming regenerative performance

    Allied recently announced that its lead regenerative tissue product CardioCel®, made using the ADAPT® process, showed significant tissue regeneration post implantation in cardiovascular repair.

    The independent validation of these latest results confirms the regenerative performance of the ADAPT® treated tissue and provides an opportunity to confirm the efficiency of the ADAPT®-treated tissue in surgical repairs and reconstructions.

    These results provide additional evidence that ADAPT® prepared tissue shows no signs of calcification and supports tissue regeneration, clear advantages over existing tissue products available.

    Revenue growth

    Bob Atwill, chief executive officer of Allied's Regenerative Medicine Division, said: "These externally validated results for Hernia repair and Pelvic Floor reconstruction, along with the recent regenerative results for CardioCel® indicate a very positive path to significant revenue growth for Allied Healthcare Group."

    "We have a great data package and will be pushing forward with our plans for a hernia product to follow on from CardioCel® which is already being used in Australia."

    Importantly, these latest results demonstrate Allied has the potential to build significant surgical tissue franchises in hernia repair, pelvic floor reconstructions, as well as other areas such as orthopaedics and as a biological scaffold to grow and deliver stem cells.

    The company is looking to present the full data at an international scientific meeting and publish the study results in a peer reviewed publication in the near future.

    Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX "Small and Mid-cap" stocks with distribution in Australia, UK, North America and Hong Kong / China.

Back To Proactive Investor's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »

Latest Comments


Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.